References
[1]
EASL
Clinical Practice Guidelines: Management of hepatocellular
carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[2]
Heimbach
J K, Kulik L M, Finn R S, et al. AASLD guidelines for the treatment of
hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380.
[3]
Bray
F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers
in 185 countries[J]. CA Cancer J Clin, 2018.
[4]
Nguyen
M H, Wong G, Gane E, et al. Hepatitis B Virus: Advances in Prevention,
Diagnosis, and Therapy[J]. Clin Microbiol Rev, 2020, 33(2).
[5]
Wong
M, Huang J, George J, et al. The changing epidemiology of liver diseases
in the Asia-Pacific region[J]. Nat Rev Gastroenterol Hepatol, 2019,
16(1): 57-73.
[6]
Singal
A G, Lampertico P, Nahon P. Epidemiology and surveillance for
hepatocellular carcinoma: New trends[J]. J Hepatol, 2020, 72(2):
250-261.
[7]
Finn R
S, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable
Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[8]
Finn R
S, Zhu A X. Evolution of Systemic Therapy for Hepatocellular
Carcinoma[J]. Hepatology, 2020.
[9]
Chen
J, Hu X, Li Q, et al. Effectiveness and safety of toripalimab,
camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus
associated hepatocellular carcinoma patients[J]. Ann Transl Med,
2020, 8(18): 1187.
[10]
Yuan
G, Cheng X, Li Q, et al. Safety and Efficacy of Camrelizumab Combined
with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein
Tumor Thrombus: A Multicenter Retrospective Study[J]. Onco Targets
Ther, 2020, 13: 12683-12693.
[11]
Paul
S, Saxena A, Terrin N, et al. Hepatitis B Virus Reactivation and
Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and
Meta-analysis[J]. Ann Intern Med, 2016, 164(1): 30-40.
[12]
Chen
C, Zhang F, Zhou N, et al. Efficacy and safety of immune checkpoint
inhibitors in advanced gastric or gastroesophageal junction cancer: a
systematic review and meta-analysis[J]. Oncoimmunology, 2019, 8(5):
e1581547.
[13]
Burns
E A, Muhsen I N, Anand K, et al. Hepatitis B Virus Reactivation in
Cancer Patients Treated With Immune Checkpoint Inhibitors[J]. J
Immunother, 2021, 44(3): 132-139.
[14]
Zhang
X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer
patients with positive Hepatitis B surface antigen undergoing PD-1
inhibition[J]. J Immunother Cancer, 2019, 7(1): 322.
[15]
Agarwal
K, Brunetto M, Seto W K, et al. 96weeks treatment of tenofovir
alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus
infection[J]. J Hepatol, 2018, 68(4): 672-681.
[16]
EASL
2017 Clinical Practice Guidelines on the management of hepatitis B virus
infection[J]. J Hepatol, 2017, 67(2): 370-398.
[17]
Lim C
J, Lee Y H, Pan L, et al. Multidimensional analyses reveal distinct
immune microenvironment in hepatitis B virus-related hepatocellular
carcinoma[J]. Gut, 2019, 68(5): 916-927.
[18]
Ho W
J, Danilova L, Lim S J, et al. Viral status, immune microenvironment and
immunological response to checkpoint inhibitors in hepatocellular
carcinoma[J]. J Immunother Cancer, 2020, 8(1).
[19]
Xuan H
N, Thi M H P, Dinh T B, et al. Association of PD-L1 gene polymorphisms
and circulating sPD-L1 levels with HBV infection susceptibility and
related liver disease progression[J]. Gene, 2022, 806: 145935.
[20]
Xu J,
Shen J, Gu S, et al. Camrelizumab in Combination with Apatinib in
Patients with Advanced Hepatocellular Carcinoma (RESCUE): A
Nonrandomized, Open-label, Phase II Trial[J]. Clin Cancer Res, 2021,
27(4): 1003-1011.
[21]
Deng
H, Kan A, Lyu N, et al. Dual Vascular Endothelial Growth Factor Receptor
and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor
Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in
Hepatocellular Carcinoma[J]. Liver Cancer, 2020, 9(3): 338-357.
[22]
Trehanpati
N, Vyas A K. Immune Regulation by T Regulatory Cells in Hepatitis B
Virus-Related Inflammation and Cancer[J]. Scand J Immunol, 2017,
85(3): 175-181.
[23]
Loomba
R, Liang T J. Hepatitis B Reactivation Associated With Immune
Suppressive and Biological Modifier Therapies: Current Concepts,
Management Strategies, and Future Directions[J]. Gastroenterology,
2017, 152(6): 1297-1309.
[24]
El-Khoueiry
A B, Sangro B, Yau T, et al. Nivolumab in patients with advanced
hepatocellular carcinoma (CheckMate 040): an open-label,
non-comparative, phase 1/2 dose escalation and expansion trial[J].
Lancet, 2017, 389(10088): 2492-2502.
[25]
Zhu A
X, Finn R S, Edeline J, et al. Pembrolizumab in patients with advanced
hepatocellular carcinoma previously treated with sorafenib
(KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet
Oncol, 2018, 19(7): 940-952.
[26]
Sun X,
Hu D, Yang Z, et al. Baseline HBV Loads Do Not Affect the Prognosis of
Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell
Death-1 Immunotherapy[J]. J Hepatocell Carcinoma, 2020, 7: 337-345.
[27]
Gane
E, Verdon D J, Brooks A E, et al. Anti-PD-1 blockade with nivolumab with
and without therapeutic vaccination for virally suppressed chronic
hepatitis B: A pilot study[J]. J Hepatol, 2019, 71(5): 900-907.
[28]
He M
K, Peng C, Zhao Y, et al. Comparison of HBV reactivation between
patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1
inhibitor and concurrent antiviral prophylaxis[J]. Cancer Immunol
Immunother, 2021.
[29]
Zhang
X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer
patients with positive Hepatitis B surface antigen undergoing PD-1
inhibition[J]. J Immunother Cancer, 2019, 7(1): 322.